Skip to main content
. 2008 Jul 24;112(7):2836–2846. doi: 10.1182/blood-2008-04-149435

Figure 2.

Figure 2

Exogenous IGF-1 enhances thymic output. Recombinant human IGF-1 was administered by continuous infusion using subcutaneously placed osmotic pumps to deliver a dose of 100 μg/day for a total of 2 weeks in 8- to 12-week-old thymus-intact female C57BL/6 mice. Pumps were replaced to deliver another 2-week course of continuous IGF-1 at 100 μg/day for a total course of 4 weeks. Combined spleen and lymph node data were obtained after 4 weeks of IGF-1 treatment: (A) CD4+ subsets; (B) CD8+ subsets; and (C) total TRECs from separated CD4+ and CD8+ T cells. Presented data are representative of 3 independent experiments, with 4 mice per group per experiment. *P < .05 between IGF-1– and diluent-treated mice. Error bars represent SEM.